BI 891065

Drug Profile

BI 891065

Alternative Names: BI 891065

Latest Information Update: 02 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 May 2017 Boehringer Ingelheim plans a phase I trial of BI 891065 in combination with BI 754091 for Cancer (Metastatic disease, Late-stage disease; Monotherapy, Combination therapy) (NCT03166631)
  • 01 May 2017 Preclinical trials in Cancer (Late-stage disease, Metastatic disease) in Germany (unspecified route) (NCT03166631)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top